Complement 3 Glomerulopathy Market size is anticipated to cross USD 68 Million by the end of 2036, growing at a CAGR of 3% during the forecast period, i.e., 2024-2036. In the year 2023, the industry size of complement 3 glomerulopathy (C3G) was over USD 45 Million. The expansion of the market has been facilitated by the close connection between nephrology and the healthy operation of several digestive processes in humans. The human body's urine bladder is crucial to preserving the health of Given these facts, it is reasonable to conclude that the secret to a long and healthy life is nephrological health. From now on, medical professionals are working nonstop to implement appropriate treatment plans for complement 3 glomerulopathy (C3G), a rare kidney illness. Also, the growing number of nephrologists is escalating the market growth. For instance, Australia employed 479 nephrologists in 2016, of whom 28.4% were employed by the private sector.
The suppliers vying for market share in the worldwide complement 3 glomerulopathy (C3G) space are developing their medications in stages. These vendors have divided their research lines based on the two forms of complement 3 glomerulopathy (C3G) that are common in humans: C3 glomerulonephritis (C3GN) and dense deposit disease (DDD). The global complement 3 glomerulopathy market has expanded due to the medical industry's push to offer treatment alternatives that are centered around diseases.
Growth Drivers
Challenges
|
Base Year |
2023 |
|
Forecast Year |
2024-2036 |
|
CAGR |
~ 3% |
|
Base Year Market Size (2023) |
~ USD 45 Million |
|
Forecast Year Market Size (2036) |
~ USD 68 Million |
|
Regional Scope |
|
Treatment Type (Anti-Complement Therapy, Cellular Immune Suppression, Plasma therapy)
Anti-complement therapy segment for the complement 3 glomerulopathy (C3G) market is expected to hold a share of 47% during the forecast period. The treatment is gaining traction because it can effectively address a variety of disorders, including C3G, that involve dysregulated complement activation. The complement system is involved in many autoimmune diseases, inflammatory ailments, and immune system abnormalities, which makes this strategy more and more crucial. Anti-complement therapy tries to moderate excessive complement activation and associated tissue damage by blocking particular components, including C3 or C5. Anti-complement therapy is anticipated to grow as a viable treatment option for a range of complement-mediated illnesses as research into complement's role in disease pathogenesis continues, as well as the development of new medicines. For instance, by developing a new class of complementary medicines for patients with classical complement-mediated autoimmune, neurodegenerative, and ophthalmic disorders, Annexon, Inc. is a clinical-stage biopharmaceutical company. The company announced encouraging final data from its open-label Phase 2 clinical trial of ANX005 in patients with Huntington's disease (HD).
End-User (Hospitals, Specialty Clinics)
Hospitals segment in the complement 3 glomerulopathy market is anticipated to hold the largest share of 55% during the forecast period. An increasing number of C3G instances are being found as a result of increased awareness and better diagnostic methods. As a result, there will be a greater need for medical services such as continuing disease management, consultations, and diagnostic testing. Additionally, in order to manage symptoms and problems, persons with C3G need to have their status regularly monitored. Support services may also be necessary. In addition, clinical trials and research studies are frequently carried out by healthcare facilities in an effort to improve knowledge and treatment choices for C3G. As a result, these elements are supporting the segment's expansion.
Our in-depth analysis of the global complement 3 glomerulopathy (C3G) market includes the following segments:
|
Treatment Type |
|
|
End-user |
|
North American Market Forecast
North American complement 3 glomerulopathy market is expected to hold a share of 36% during the forecast period. The increase can be attributed to the region's increasing incidence of kidney disorders. Additionally, the region's growing hospital and specialty clinic population is fueling market expansion.
European Market Statistics
Complement 3 glomerulopathy market in Europe is poised to grow with a share of 28% by the end of 2036. Europe has come a long way in creating and implementing sophisticated kidney disease diagnostic methods, such as C3G. Additionally, the number of clinical studies for the illness being conducted in the area is driving the market's expansion. The regulatory landscape in Europe is favorable to the creation and monetization of orphan medications and the management of uncommon illnesses such as C3G.
Author Credits: Smruti Ranjan, Rajrani Baghel
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?